Moreover, at difference with the significant AKT activation shown by NSCLCs with mutant KRAS or AKT1, the tumour that harboured mutant PIK3CA was negative for pAKT, suggesting that the type or the position of the alteration within the pathway may influence mechanisms and effects of pathway deregulation [45], [49]–[51]. Here, KRAS is linked to neoplasm.